AU2000258650A1 - 2-piperidone compounds for the treatment of cancer - Google Patents
2-piperidone compounds for the treatment of cancerInfo
- Publication number
- AU2000258650A1 AU2000258650A1 AU2000258650A AU5865000A AU2000258650A1 AU 2000258650 A1 AU2000258650 A1 AU 2000258650A1 AU 2000258650 A AU2000258650 A AU 2000258650A AU 5865000 A AU5865000 A AU 5865000A AU 2000258650 A1 AU2000258650 A1 AU 2000258650A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- treatment
- piperidone compounds
- piperidone
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2000/000646 WO2001085716A1 (en) | 2000-05-11 | 2000-05-11 | 2-piperidone compounds for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2000258650A1 true AU2000258650A1 (en) | 2001-11-20 |
Family
ID=21740965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2000258650A Abandoned AU2000258650A1 (en) | 2000-05-11 | 2000-05-11 | 2-piperidone compounds for the treatment of cancer |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2004507457A (en) |
| AU (1) | AU2000258650A1 (en) |
| WO (1) | WO2001085716A1 (en) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861530B2 (en) * | 2000-07-07 | 2005-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Piperidine derivatives |
| ES2321509T3 (en) | 2002-11-26 | 2009-06-08 | Pfizer Products Inc. | PIPERIDINE COMPOUNDS REPLACED WITH PHENYL FOR USE AS PPAR ACTIVATORS. |
| TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
| WO2008069313A1 (en) * | 2006-12-07 | 2008-06-12 | Japan Tobacco Inc. | Method for producing pyrrolidine compound |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| PT2203439E (en) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 1`,3`-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1`h-ý1, 4`¨bipyridinyl-2`-ones |
| EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
| CN102232074B (en) | 2008-11-28 | 2014-12-03 | 奥梅-杨森制药有限公司 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| CA2760741C (en) | 2009-05-12 | 2018-05-01 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| ES2409006T3 (en) | 2009-05-12 | 2013-06-24 | Janssen Pharmaceuticals Inc. | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| JP5852665B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
| CA2815002C (en) | 2010-11-08 | 2019-10-22 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| CN103298810B (en) | 2010-11-08 | 2016-03-16 | 杨森制药公司 | The purposes of 1,2,4-triazolo [4,3-a] pyridine derivate and the positive allosteric modulators as MGLUR2 acceptor thereof |
| JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
| KR20200036063A (en) | 2014-01-21 | 2020-04-06 | 얀센 파마슈티카 엔.브이. | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
| JP6629740B2 (en) | 2014-01-21 | 2020-01-15 | ヤンセン ファーマシューティカ エヌ．ベー． | Combinations comprising metabolic glutamatergic receptor subtype 2 positive allosteric modulators or orthosteric agonists and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
-
2000
- 2000-05-11 AU AU2000258650A patent/AU2000258650A1/en not_active Abandoned
- 2000-05-11 WO PCT/US2000/000646 patent/WO2001085716A1/en active Application Filing
- 2000-05-11 JP JP2001582317A patent/JP2004507457A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004507457A (en) | 2004-03-11 |
| WO2001085716A1 (en) | 2001-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002222853A1 (en) | Therapeutic compounds | |
| AU2020501A (en) | Chemotherapy treatment | |
| AU2935200A (en) | Compounds for the treatment of obesity | |
| AU2002223827A1 (en) | Well treatment | |
| AU2001272849A1 (en) | Composition for the treatment of osteoarthritis | |
| AU2002348135A1 (en) | Methods for the treatment of addiction | |
| AU2001247474A1 (en) | Compounds for the treatment of psychiatric or substance abuse disorders | |
| AU2001272852A1 (en) | Composition for the treatment of migraine | |
| AU2000258650A1 (en) | 2-piperidone compounds for the treatment of cancer | |
| EP1176964B8 (en) | Uses of et743 for treating cancer | |
| AU2000276362A1 (en) | Composition for the treatment of diabetes | |
| AU2002240359A1 (en) | Pharmaceutical composition for the treatment of alopecia | |
| AU2002217866A1 (en) | Geldanamycin derivatives useful for the treatment of cancer | |
| AU2001290165A1 (en) | Components of canola for the treatment of cancer | |
| AU8322401A (en) | Indole compounds useful for the treatment of cancer | |
| AU2002353739A1 (en) | Therapeutic compounds | |
| AU3997700A (en) | Anti-first-pass effect compounds | |
| AU2002308642A1 (en) | Methods for treating cancer | |
| AU5547000A (en) | Novel treatment | |
| AU7363000A (en) | Method for reducing the risk of cancer | |
| AU2021601A (en) | Composition for the treatment of dandruff | |
| AU7636800A (en) | Improved ricin-like toxins for treatment of cancer | |
| AU2001214116A1 (en) | Novel paclitaxel derivatives for the treatment of cancer | |
| AU4556800A (en) | Novel treatment | |
| AU2002225327A1 (en) | Apparatus for aesthetic treatment |